Clinical trials: Esophageal Varices
Variceal Bleeding, Ultrasonography
Ultrasound Prediction of Esophageal Variceal Bleeding Risk
This prospective observational study aims to evaluate the accuracy of using routine abdominal ultrasound to predict the risk of esophageal variceal bleeding in adult patients with liver cirrhosis.
- Conditions
- Variceal Bleeding, Ultrasonography, Esophageal Bleeding, Esophageal Varices
- Trial name
- NCT07571876
- Volunteers
- 165 people
- Sponsor
- Assiut University
Portal Hypertension, Portal Vein Thrombosis
Preemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis
Portal vein thrombosis (PVT) can lead to a further increase in portal venous pressure and increase the risk of rebleeding. Whether patients with acute esophagogastric variceal bleeding with occlusive PVT benefit from preemptive…
- Conditions
- Portal Hypertension, Portal Vein Thrombosis, Esophageal Varix Bleeding, Portosystemic Shunt
- Trial name
- NCT06122753
- Testing
- preemptive TIPS, standard second prophylaxis
- Where
- China
- Volunteers
- 120 people
- Sponsor
- West China Hospital
Chronic Liver Disease, Esophageal Varices
Blood Ammonia as Predictor for Esophageal Varices and Risk of Bleeding
Assessment of blood ammonia level as a non-invasive predictor for presence of EV and risk of bleeding
- Trial name
- EV (NCT03212872)
- Testing
- Endoscopy
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Tanta University
Esophageal Varices, Gastric Varices
Evaluation of Gastroesophageal Varices by Transnasal Endoscopy.
The study aims to evaluate the feasibility of transnasal endoscopy in patients with portal hypertension, cirrhotic and non-cirrhotic.
- Conditions
- Esophageal Varices, Gastric Varices, Hypertension Portal, Liver Cirrhosis
- Trial name
- NCT02767206
- Volunteers
- 50 people
- Sponsor
- Federal University of Minas Gerais
Cirrhosis, Hypertension, Portal
Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding
This is a prospective, double blind controlled trial in which patients with esophagic variceal bleeding treated with standard therapy (endoscopic variceal ligation(EVL) + B-blockers), will be randomized to receive statins or…
- Conditions
- Cirrhosis, Hypertension, Portal, Bleeding Esophageal Varices, Portal Vein Thrombosis
- Trial name
- NCT01095185
- Testing
- Simvastatin
- Where
- 15 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Juan A. Arnaiz
Liver Cirrhosis, Portal Hypertension
Extension Study of Carvedilol RCT Study
Patients who have completed 2-years treatment in RCT Study of carvedilol will receive another 2-years extension therapy, aiming to investigate the long-term efficacy of carvedilol for the prevention of esophageal varices in…
- Trial name
- NCT05021406
- Testing
- Carvedilol 12.5 MG
- Where
- 14 sites in China
- Volunteers
- 240 people
- Sponsor
- Beijing Friendship Hospital
Varicose Veins, Chronic Venous Insufficiency
The Influence of Laser Crossectomy With Different Wavelengths on Varicose Vein Progression
Technically successful laser crossectomy will reduce the risk of reflux recurrence at the sapheno-femoral junction without increasing the risk of endovenous heat-induced thrombosis, which may positively impact the likelihood of…
- Trial name
- LACROSS-VVP (NCT07449728)
- Testing
- Laser crossectomy on 1470 nm, Laser crossectomy on 1940 nm, Standard EVLT with a stump
- Where
- Russia
- Volunteers
- 400 people
- Sponsor
- Pirogov Russian National Research Medical University
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG